Markets:

Overview

News

Currencies

International

Treasuries

Alcon Inc. Ordinary Shares (NY:ALC)

70.77 +0.56 (+0.80%)

Streaming Delayed Price Updated: 1:32 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Alcon Agrees to Acquire STAAR Surgical

August 05, 2025

From Alcon Inc. Investors

Via Business Wire

Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

July 22, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Alcon Earnings Preview ↗

May 12, 2025

Via Benzinga

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

July 07, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 ↗

May 29, 2025

FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

Via Benzinga

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

May 28, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

May 14, 2025

Via Benzinga

American Eagle, Cisco Systems And 3 Stocks To Watch Heading Into Wednesday ↗

May 14, 2025

Via Benzinga

Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

May 13, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Announces Results of 2025 Annual General Meeting

May 06, 2025

From Alcon Inc. Investors

Via Business Wire

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

April 25, 2025

From Alcon Inc. Investors

Via Business Wire

3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield

April 16, 2025

Via MarketBeat

Alcon Publishes Agenda for 2025 Annual General Meeting

April 04, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

April 02, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

March 26, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

March 25, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Eyes Surgical Edge With LENSAR Buyout: Details ↗

March 24, 2025

Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted cataract...

Via Benzinga

Alcon Agrees to Acquire LENSAR, Inc.

March 24, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon to Host 2025 Capital Markets Day

March 13, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters

February 27, 2025

From Alcon Canada

Via Business Wire

Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation

February 25, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet

February 24, 2025

From Alcon Inc. Investors

Via Business Wire

Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension

February 19, 2025

From Alcon Inc. Investors

Via Business Wire

Apple To $253? Here Are 10 Top Analyst Forecasts For Friday ↗

January 24, 2025

Via Benzinga

Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference

December 31, 2024

From Alcon Inc. Investors

Via Business Wire

Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

December 17, 2024

Via Benzinga

Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation

November 12, 2024

From Alcon Inc. Investors

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.